The Marsh & McLennan Companies, Inc. (MMC) Stake Increased by Mn Services Vermogensbeheer B.V.

The Marsh & McLennan Companies, Inc. (MMC) Stake Increased by Mn Services Vermogensbeheer B.V.

Other large investors also recently made changes to their positions in the company. FNY Partners Fund LP bought a new stake in shares of Marsh & McLennan Companies during the fourth quarter worth about $101,000. Seven Bridges Advisors LLC boosted its stake in Marsh & McLennan Companies by 21.0% in the third quarter. Seven Bridges Advisors LLC now owns 1,524 shares of the financial services provider’s stock valued at $102,000 after buying an additional 264 shares in the last quarter. Advantage Investment Management LLC acquired a new stake in Marsh…

The Exelon Co. (EXC) Stake Boosted by Mn Services Vermogensbeheer B.V.

The Exelon Co. (EXC) Stake Boosted by Mn Services Vermogensbeheer B.V.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Regal Investment Advisors LLC increased its position in shares of Exelon by 30.6% in the third quarter. Regal Investment Advisors LLC now owns 15,521 shares of the energy giant’s stock worth $517,000 after buying an additional 3,634 shares during the period. Brighton Jones LLC purchased a new position in shares of Exelon during the third quarter worth about $387,000. Proffitt & Goodson Inc. increased its position in shares of Exelon by 3.0% in…

The Mn Services Vermogensbeheer B.V. Raises Stake in Boston Scientific Co. (BSX)

The Mn Services Vermogensbeheer B.V. Raises Stake in Boston Scientific Co. (BSX)

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Boston Private Wealth LLC increased its position in Boston Scientific by 0.4% in the third quarter. Boston Private Wealth LLC now owns 22,890 shares of the medical equipment provider’s stock valued at $545,000 after buying an additional 85 shares during the last quarter. Wade G W & Inc. increased its position in Boston Scientific by 0.9% in the third quarter. Wade G W & Inc. now owns 22,177 shares of the medical equipment…

The Community Trust Bancorp, Inc. (CTBI) Upgraded by Hilliard Lyons to Neutral

The Community Trust Bancorp, Inc. (CTBI) Upgraded by Hilliard Lyons to Neutral

A number of other research firms have also weighed in on CTBI. Sandler O’Neill raised shares of Community Trust Bancorp from a sell rating to a hold rating in a research note on Wednesday, March 29th. Zacks Investment Research raised shares of Community Trust Bancorp from a hold rating to a buy rating and set a $54.00 price objective on the stock in a research note on Tuesday, January 10th. Hilliard Lyons upgraded shares of Community Trust Bancorp, Inc. (NASDAQ:CTBI) from an underperform rating to a neutral rating in a…

The Gilead Sciences’ (GILD) Buy Rating Reaffirmed at Piper Jaffray Companies

The Gilead Sciences’ (GILD) Buy Rating Reaffirmed at Piper Jaffray Companies

A number of other research analysts have also weighed in on the stock. Maxim Group reissued a hold rating on shares of Gilead Sciences in a report on Friday. Vetr raised shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $74.58 target price for the company in a report on Tuesday, April 18th. Cowen and Company reissued a buy rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Monday, April 17th. Zacks Investment Research raised shares of…

The Tristate Capital Holdings Inc (TSC) Price Target Increased to $28.00 by Analysts at Maxim Group

The Tristate Capital Holdings Inc (TSC) Price Target Increased to $28.00 by Analysts at Maxim Group

Several other equities research analysts also recently weighed in on TSC. Zacks Investment Research downgraded Tristate Capital Holdings from a buy rating to a hold rating in a report on Thursday, December 29th. DA Davidson initiated coverage on Tristate Capital Holdings in a report on Monday, March 6th. They set a buy rating and a $29.00 price target for the company. They noted that the move was a valuation call. Tristate Capital Holdings Inc (NASDAQ:TSC) had its price target increased by Maxim Group from $25.00 to $28.00 in a research…

The Steven Madden, Ltd. (SHOO) Given a $41.00 Price Target by Piper Jaffray Companies Analysts

The Steven Madden, Ltd. (SHOO) Given a $41.00 Price Target by Piper Jaffray Companies Analysts

A number of other research firms have also recently weighed in on SHOO. Jefferies Group LLC reaffirmed a hold rating and set a $37.00 target price on shares of Steven Madden in a research note on Monday, April 3rd. Zacks Investment Research raised shares of Steven Madden from a sell rating to a hold rating in a research note on Friday, March 3rd. Citigroup Inc reaffirmed a focus list rating on shares of Steven Madden in a research note on Tuesday, March 7th. B. Riley raised shares of Steven Madden…

The Starbucks Co. (SBUX) Downgraded by Zacks Investment Research to “Hold”

The Starbucks Co. (SBUX) Downgraded by Zacks Investment Research to “Hold”

According to Zacks, “Starbucks is strengthening its portfolio with significant innovation around beverages and core food offerings. Starbucks’s operating fundamentals remain strong – solid global retail footprint, successful innovations, best-in-class loyalty program and digital offerings. Again, digital initiatives like mobile order/pay, delivery services and third-party loyalty partnerships can stimulate stronger sales trends in the Americas. CPG growth across the world as well as China/Asia expansion will also enhance value creation. Starbucks’ shares have outperformed the Zacks categorized Retail-Food & Restaurants industry so far this year. However, economic, geopolitical and consumer…

The Neurocrine Biosciences (NBIX) – Research Analysts’ Weekly Ratings Changes

The Neurocrine Biosciences (NBIX) – Research Analysts’ Weekly Ratings Changes

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded up 1.4319% during trading on Monday, hitting $51.8317. 655,396 shares of the stock were exchanged. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $55.15. The stock’s market cap is $4.52 billion. The stock has a 50 day moving average of $45.02 and a 200-day moving average of $44.30. A number of firms have modified their ratings and price targets on shares of Neurocrine Biosciences (NASDAQ: NBIX) recently: Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on…

The Analysts Anticipate Otter Tail Co. (OTTR) Will Announce Earnings of $0.44 Per Share

The Analysts Anticipate Otter Tail Co. (OTTR) Will Announce Earnings of $0.44 Per Share

On average, analysts expect that Otter Tail will report full-year earnings of $1.71 per share for the current year, with EPS estimates ranging from $1.70 to $1.71. For the next financial year, analysts expect that the firm will post earnings of $1.81 per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Otter Tail. Analysts expect that Otter Tail Co. (NASDAQ:OTTR) will report earnings per share of $0.44 for the current quarter, according to Zacks. Zero analysts have…